Personalised Medicine: Let’s be clear what it means

April 2008. Genentech, Chugai, Ventana … the list of Roche’s major acquisitions is impressive over the last decades. To this add health projects involving entire nations such as Iceland. In the interview Jonathan Knowles describes what motivates him in Roche. How to improve efficiency of clinical trials and diagnostic development comparing the company to peer performance. Clearly genetics and genomics will not guarantee success.Reading time: 19 min

Read Now:
1,00 EUR (incl. 7% VAT)

Back to section